SIRT1 and metabolic dysfunction-associated steatotic liver disease: These data indicate that SIRT1 activator E1231 ameliorated lipid accumulation and thus protected against NAFLD in both FFA-challenged hepatocytes and HFHC-induced NAFLD mice.